Prediction: The Nasdaq's AI Stocks Will Outperform the S&P 500 Over the Next 12 Months. Here's What to Buy.

Nasdaq-100 earnings growth is running ahead of the S&P 500, with 2025 net income growth cited as stronger and Q1 2026 expected to rise 19% year over year versus 11% for the S&P 500. The article argues AI spending and adoption should keep supporting tech earnings, highlighting CoreWeave's $90 billion backlog, planned $30 billion-$35 billion 2026 capex, and Microsoft's 15 million paid Microsoft 365 Copilot seats. CoreWeave shares jumped 49% in April, while Microsoft trades at 22x forward earnings versus 23.6x for the Nasdaq-100.

Analysis

The key setup is not simply “AI is good,” but that earnings dispersion within large-cap tech should widen materially as capex intensity shifts from a cost center to a demand signal. Hyperscaler spend and neocloud buildout should create a reflexive loop: more infrastructure spend lifts semiconductor, networking, power, and cooling demand first, then monetization follows with a lag as enterprise AI usage converts into software ARPU and seat expansion. That favors the platforms with both distribution and balance-sheet flexibility; it is more fragile for capital-intensive newcomers that need flawless execution to finance growth.

CoreWeave is the clearest beneficiary on momentum, but it is also the most vulnerable to a reversal in financing conditions because its equity story is still tied to backlog conversion and continuous external capital. The market is likely underwriting a scarcity premium for AI compute capacity, yet that premium can compress quickly if hyperscalers internalize more capacity, if GPU supply normalizes, or if contract concentration becomes a focus. The second-order winner is the broader AI infrastructure stack: NVDA, networking, memory, and power-management names should see a cleaner, less binary earnings path than the pure-play neoclouds.

Microsoft is the higher-quality expression of the same theme because AI attach rates can lift revenue per user without the same balance-sheet strain. The market may still be underestimating how much of Copilot adoption is a seat-expansion story versus a productivity feature, which matters because the former is more durable and margin-accretive. Near term, the main risk is that AI software adoption looks strong in pilots but slower in enterprise-wide rollout, which would cap multiple expansion even if the narrative stays positive.

Contrarianly, the move in AI proxies may be partly a re-rating on sentiment rather than an earnings revision cycle that is fully visible yet. That means the trade likely works best over 3-6 months if earnings guides confirm the capex-to-revenue conversion, but it can fail quickly on any signal of slower procurement, delayed data-center ramps, or tighter cloud economics. The market is rewarding visible demand; the hidden risk is that capacity buildout outruns monetization for longer than bulls expect.

Key Decisions for Investors

• Long MSFT into the next earnings cycle; preferred high-quality AI exposure with lower execution risk. Target a 6-12 month hold for multiple expansion if Copilot seat growth and Azure AI monetization continue; risk/reward is attractive versus higher-beta AI names.
• Trade pair: long MSFT / short CRWV in equal dollar terms for a 3-6 month window. Thesis: monetize the AI demand wave through a balance-sheet compounder while fading the capital-intensive name most exposed to financing and backlog-conversion risk; stop if CRWV demonstrates improving gross margin and self-funding capex.
• For more aggressive accounts, buy NVDA on pullbacks rather than chasing CRWV strength. The better second-order exposure is to the picks-and-shovels layer with pricing power and supply scarcity; use a 2-4 month horizon tied to hyperscaler capex commentary.
• If using options, consider MSFT call spreads expiring after the next two earnings reports. This captures upside from AI software re-acceleration while defining downside if enterprise adoption proves less durable than expected.
• Avoid initiating fresh long CRWV at elevated multiples unless size is small and hedged. The stock has momentum, but the risk/reward deteriorates quickly if backlog growth slows, funding costs rise, or investors shift from revenue growth to cash burn scrutiny.